阿德福韦酯与拉米夫定治疗慢性乙型肝炎对比分析(1)
 |
| 第1页 |
参见附件(2896KB，3页)。
[摘要] 目的 比较阿德福韦酯(贺维力)与拉米夫定(贺普丁)治疗慢性活动性乙型肝炎的临床疗效，以提高有效率，减少耐药性。方法 收集我院2008年12月~ 2011年1月经消化内科应用上述两种药物系统治疗慢性活动性乙型肝炎患者150例，根据用药分为三组各50例：分别为使用贺维力、贺普丁及两种药物合用。分别于治疗的12 、24 、36 、52周观察HBV-DNA病毒复制情况及ALT阴转率，比较各组间患者的临床疗效。结果 贺维力组连续治疗52周，各时期HBV-DNA转阴率分别为32.0%、54.0%、62.0%、74.0%；贺普丁组分别为48.0%、52.0%、52.0%、66.0%；联合用药组分别为48.0%、54.0%、68.0%、78.0%。经过贺维力组连续治疗52周，各时期ALT转阴率分别为30.0%、44.0%、76.0%、70.0%；贺普丁组分别为60.0%、68.0%、80.0%、72.0%；联合用药组分别为62.0%、66.0%、74.0%、74.0%。结论 治疗52周时，贺维力组HBV-DNA及ALT转阴率略好于贺普丁组，与联合用药组无明显差异。
[关键词] 贺维力；贺普丁；慢性活动性乙型肝炎
[中图分类号] R512.6+2 [文献标识码] B [文章编号] 1673-9701(2011)33-46-02
Comparative Study of Adefovir Dipivoxil and Lamivudine in the Treatment of Chronic Hepatitis B
QU Lichun1 ZHAO Hai2 ZHAO Hongran3 LAN Lan1
1. MRI Room, Daqing Oil Field General Hospital, Daqing 163001, China;2.Department of Radiology, Daqing Ranghulu Railway Hospital,Daqing163712, China; 3.Medical Device Division, Daqing Ranghulu Railway Hospital,Daqing 163712, China
[Abstract] Objective To compare the power of Adefovir dipivoxil and Lamivudine in the treatment of chronic active hepatitis B clinical efficacy,so as to improve efficiency. Methods All of 150 cases were collected which were treated by two drugs we mentioned in our hospital from Desember 2008 to Janury 2011. All cases in three groups according the treatment: group 1:Adefovir Dipivoxil; group 2: Lamivudine ; Group 3: two drugs combination used, 50 cases respectively.in the treatment of 12 weeks, 24 weeks, 36 weeks, 52 weeks observed HBV-DNA viral replication and ALT negative rate, comparing the clinical efficacy between every two groups ,and analysis the result. Results After 52 weeks treatment, in group 1 the HBV-DNA negative rates were 32.0%, 54.0%, 62.0%, 74.0%; in group 2: 48.0%, 52.0%, 52.0%, 66.0%; in group 3: 48.0%, 54.0%, 68.0%, 78.0%. After continuous treatment by Adefovir Dipivoxil for 52 weeks, the ALT negative rates were,1:30.0%, 44.0%, 76.0%, 70.0%; group 2: 60 ......
您现在查看是摘要介绍页，详见PDF附件(2896KB，3页)。